Stockreport

Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting [Yahoo! Financ...

Werewolf Therapeutics, Inc.  (HOWL) 
PDF WTX-712, a conditionally activated IL-21 INDUKINE TM molecule has potent antitumor activity in preclinical models with a differentiated immune activation mechanism WA [Read more]